221 related articles for article (PubMed ID: 25723369)
21. Biosimilars: Hope and concern.
Emmanouilides CE; Karampola MI; Beredima M
J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
[TBL] [Abstract][Full Text] [Related]
22. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
Berreur B; Guerin F; Christophe B; Limido G; Paubel P
Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
[TBL] [Abstract][Full Text] [Related]
23. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
[TBL] [Abstract][Full Text] [Related]
24. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
25. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
26. Biosimilars: a new era in access to breast cancer treatment.
The Lancet
Lancet; 2020 Jan; 395(10217):2. PubMed ID: 31908273
[No Abstract] [Full Text] [Related]
27. Iraqi regulatory authority current system and experience with biosimilars.
Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
[TBL] [Abstract][Full Text] [Related]
28. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
[TBL] [Abstract][Full Text] [Related]
29. Medical specialists' attitudes to prescribing biosimilars.
Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
[TBL] [Abstract][Full Text] [Related]
30. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
31. Obstacles to the Adoption of Biosimilars for Chronic Diseases.
Hakim A; Ross JS
JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924
[No Abstract] [Full Text] [Related]
32. [Biosimilars: current reality, promising future?].
Agustí Escasany A; Rodríguez Cumplido D
Med Clin (Barc); 2015 Jul; 145(1):18-20. PubMed ID: 25978924
[No Abstract] [Full Text] [Related]
33. [The importance of biosimilars medicines for private and statutory health insurance].
Bretthauer B
Versicherungsmedizin; 2016 Dec; 68(4):173-5. PubMed ID: 29144116
[TBL] [Abstract][Full Text] [Related]
34. Biologicals and how they revolutionized rheumatology.
Grisar J
Wien Med Wochenschr; 2015 Jan; 165(1-2):1-2. PubMed ID: 25676698
[No Abstract] [Full Text] [Related]
35. Greater potential cost savings with biosimilar use.
Yu B
Am J Manag Care; 2016 May; 22(5):378. PubMed ID: 27266439
[No Abstract] [Full Text] [Related]
36. Bullying biosimilars: cheaper drugs stymied in USA.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
[No Abstract] [Full Text] [Related]
37. Rumors of the Death of Biosimilars Have Been Greatly Exaggerated.
Lyman GH; Kuderer N
Cancer Invest; 2019; 37(8):325-326. PubMed ID: 31500458
[No Abstract] [Full Text] [Related]
38. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
Patel D; Park KT
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
[TBL] [Abstract][Full Text] [Related]
39. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
40. How do biosimilars sustain value, affordability, and access to oncology care?
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
